WallStSmart

Merck & Company Inc (MRK)vsNeOnc Technologies Holdings, Inc. Common Stock (NTHI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 164461020% more annual revenue ($65.77B vs $39,990). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9

NTHI

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -80.68
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.8%)

Margin of Safety

-13.8%

Fair Value

$97.84

Current Price

$111.38

$13.54 premium

UndervaluedFair: $97.84Overvalued

Intrinsic value data unavailable for NTHI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

NTHI1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

NTHI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$137.81M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : NTHI

The strongest argument for NTHI centers on Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : NTHI

The primary concerns for NTHI are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 14/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

NeOnc Technologies Holdings, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

NeOnc Technologies Holdings, Inc. is a forward-thinking biotechnology firm dedicated to revolutionizing cancer treatment through advanced immunotherapy and molecular medicine. With a strong pipeline of innovative product candidates targeting crucial unmet needs in oncology, the company is strategically positioned to reshape treatment paradigms and enhance patient outcomes. Its collaborative partnerships within the biopharmaceutical arena further bolster its capabilities in bringing therapeutic innovations to market, rendering NeOnc a compelling investment prospect within the burgeoning cancer therapeutics sector.

Visit Website →

Want to dig deeper into these stocks?